Does Advair Contain a Steroid?
Yes, Advair contains fluticasone propionate, which is an inhaled corticosteroid (steroid). 1, 2
Composition of Advair
Advair is a fixed-dose combination inhaler containing two active medications:
- Fluticasone propionate – a synthetic corticosteroid with potent anti-inflammatory activity 1, 2
- Salmeterol – a long-acting beta2-adrenergic agonist (LABA) bronchodilator 1, 2
Steroid Component Details
Fluticasone propionate is a trifluorinated corticosteroid that exhibits binding affinity for the human glucocorticoid receptor 18 times greater than dexamethasone, almost twice that of beclomethasone-17-monopropionate, and over 3 times that of budesonide. 1
- The corticosteroid component treats the underlying inflammatory process in asthma by acting on multiple cell types (mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (histamine, eicosanoids, leukotrienes, cytokines) involved in airway inflammation 1
Available Strengths
Advair Diskus is available in three strengths, all containing a fixed 50 mcg dose of salmeterol combined with varying doses of the steroid fluticasone propionate:
- 100/50 mcg (100 mcg fluticasone propionate + 50 mcg salmeterol) 1, 2
- 250/50 mcg (250 mcg fluticasone propionate + 50 mcg salmeterol) 1, 2
- 500/50 mcg (500 mcg fluticasone propionate + 50 mcg salmeterol) 1, 2
Clinical Rationale for the Combination
The combination addresses both the inflammatory and bronchoconstrictive components of asthma by delivering anti-inflammatory corticosteroid therapy together with long-acting bronchodilation in a single inhaler. 2, 3
- Combination therapy with inhaled corticosteroids plus long-acting beta2-agonists is recommended as the most effective treatment for moderate persistent asthma (step 3 care) 4
- Long-acting beta2-agonists cannot substitute for inhaled corticosteroids and must always be used in combination with a steroid component 4, 5
Important Safety Consideration
The FDA requires a black-box warning on all LABA-containing products (including Advair) mandating that LABAs must never be used as monotherapy without an inhaled corticosteroid, as LABA monotherapy increases the risk of severe exacerbations and asthma-related death. 5, 6